ECSP22076278A - Conjugados para reactividad selectiva a dioles vecinales - Google Patents

Conjugados para reactividad selectiva a dioles vecinales

Info

Publication number
ECSP22076278A
ECSP22076278A ECSENADI202276278A ECDI202276278A ECSP22076278A EC SP22076278 A ECSP22076278 A EC SP22076278A EC SENADI202276278 A ECSENADI202276278 A EC SENADI202276278A EC DI202276278 A ECDI202276278 A EC DI202276278A EC SP22076278 A ECSP22076278 A EC SP22076278A
Authority
EC
Ecuador
Prior art keywords
vicinal
diols
diol
sensors
drug substance
Prior art date
Application number
ECSENADI202276278A
Other languages
English (en)
Inventor
Sachitanand Mali
Diao Chen
Jack Joseph Steele
Alborz Mahdavi
Ryan Kelly Spencer
Jingxin Liang
Mirna Ekram Anwar Shaker
Original Assignee
Protomer Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protomer Tech Inc filed Critical Protomer Tech Inc
Publication of ECSP22076278A publication Critical patent/ECSP22076278A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Abstract

Las modalidades de la presente descripción refieren a sensores que pueden unirse selectivamente a dioles vecinales específicos en presencia de otros dioles. Estos compuestos boronados de sensores que responden a dioles vecinales pueden detectar niveles de dioles vecinales específicos y responder a estas moléculas en el cuerpo. En determinadas modalidades, el diol vecinal es un cis diol, por ejemplo, una hexosa tal como la glucosa. En determinadas modalidades, los sensores se conjugan con una sustancia farmacológica, y los sensores pueden cambiar las características biofísicas, la farmacocinética y/o la actividad de la sustancia farmacológica en respuesta al diol vecinal. La sustancia farmacológica puede ser o incluir un polipéptido, tal como una insulina, un péptido endocrino o de incretina humano, o un análogo de este, y puede contener uno o más aminoácidos modificados que contienen un sensor que responde al diol vecinal.
ECSENADI202276278A 2020-03-31 2022-09-30 Conjugados para reactividad selectiva a dioles vecinales ECSP22076278A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063002662P 2020-03-31 2020-03-31

Publications (1)

Publication Number Publication Date
ECSP22076278A true ECSP22076278A (es) 2022-12-30

Family

ID=75588297

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202276278A ECSP22076278A (es) 2020-03-31 2022-09-30 Conjugados para reactividad selectiva a dioles vecinales

Country Status (17)

Country Link
US (1) US20230134116A1 (es)
EP (1) EP4126058A1 (es)
JP (1) JP2023520049A (es)
KR (1) KR20220161422A (es)
CN (1) CN115843257A (es)
AU (1) AU2021247169A1 (es)
BR (1) BR112022019687A2 (es)
CA (1) CA3173417A1 (es)
CL (1) CL2022002662A1 (es)
CO (1) CO2022014157A2 (es)
CR (1) CR20220555A (es)
EC (1) ECSP22076278A (es)
GB (1) GB2610490A (es)
IL (1) IL296804A (es)
MX (1) MX2022012208A (es)
PE (1) PE20230457A1 (es)
WO (1) WO2021202802A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022109078A1 (en) * 2020-11-19 2022-05-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US906028A (en) 1908-03-27 1908-12-08 Herbert E Jennison Adjustable foot-block for radiators.
US4421685A (en) 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
EP0792290B1 (en) 1993-09-17 2001-08-29 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
AR002976A1 (es) 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
CA2306877A1 (en) 1997-10-24 1999-05-06 Eli Lilly And Company Insoluble insulin compositions
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
WO1999034821A1 (en) 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
WO2003048195A2 (en) * 2001-12-02 2003-06-12 Novo Nordisk A/S Glucose dependant release of insulin from glucose sensing insulin derivatives
AU2003248370A1 (en) 2002-02-27 2003-09-09 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
ATE496064T1 (de) 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
EP1713440A4 (en) 2004-01-23 2009-10-28 California Inst Of Techn GENETIC GENE PROTEINS, AND METHODS OF MAKING AND USING THE SAME
AU2005211362B2 (en) 2004-02-02 2008-03-13 Ambrx, Inc. Modified human interferon polypeptides and their uses
NZ555386A (en) 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
JP4990792B2 (ja) 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド アミノアシル−ｔＲＮＡシンテターゼの組成物およびこの使用
WO2007047668A2 (en) 2005-10-14 2007-04-26 California Institute Of Technology Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells
PT1999259E (pt) 2006-03-03 2014-09-24 California Inst Of Techn Incorporação sítio-específica de aminoácidos em moléculas
EP2395099A3 (en) 2006-05-02 2012-05-16 Allozyne, Inc. Amino acid substituted molecules
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2930182A1 (en) 2007-11-20 2015-10-14 Ambrx, Inc. Modified insulin polypeptides and their uses
US9996862B2 (en) 2012-07-23 2018-06-12 @Pay Ip Holdings Llc Point of sale email-based e-commerce
WO2014093696A2 (en) * 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
EP3154568A4 (en) 2014-06-10 2018-01-24 California Institute of Technology Non-canonical insulins and their uses
WO2017070617A1 (en) * 2015-10-21 2017-04-27 Case Western Reserve University Diol-modified insulin analogues containing a glucose-regulated conformational switch
WO2019092125A1 (en) * 2017-11-09 2019-05-16 Novo Nordisk A/S Glucose-sensitive albumin-binding derivatives
KR20210005630A (ko) * 2018-04-16 2021-01-14 유니버시티 오브 유타 리서치 파운데이션 글루코스-반응성 인슐린
MX2021010988A (es) * 2019-03-29 2021-10-01 Novo Nordisk As Derivados de insulina sensibles a la glucosa.
US20220288213A1 (en) * 2019-07-31 2022-09-15 Thermalin Inc. Insulin analogues with glucose regulated conformational switch

Also Published As

Publication number Publication date
GB202214274D0 (en) 2022-11-16
WO2021202802A1 (en) 2021-10-07
AU2021247169A1 (en) 2022-10-20
PE20230457A1 (es) 2023-03-10
CN115843257A (zh) 2023-03-24
US20230134116A1 (en) 2023-05-04
CA3173417A1 (en) 2021-10-07
BR112022019687A2 (pt) 2022-12-20
GB2610490A (en) 2023-03-08
JP2023520049A (ja) 2023-05-15
CO2022014157A2 (es) 2023-03-27
EP4126058A1 (en) 2023-02-08
IL296804A (en) 2022-11-01
MX2022012208A (es) 2022-12-15
CL2022002662A1 (es) 2023-07-21
KR20220161422A (ko) 2022-12-06
CR20220555A (es) 2023-01-23

Similar Documents

Publication Publication Date Title
ECSP22076278A (es) Conjugados para reactividad selectiva a dioles vecinales
CY1121042T1 (el) Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως
Amiram et al. Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control
PE20220283A1 (es) Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un medicamento
AR077454A1 (es) Preparaciones insulinicas que comprenden metionina
BRPI0508421A (pt) sistemas de transporte biológico de múltiplos componentes
ES2131069T3 (es) Expresion de proteinas recombinantes en bacterias atenuadas.
AR072596A1 (es) Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico
PE20121643A1 (es) Polipeptidos del factor ix modificados y usos de los mismos
BRPI0508440A (pt) composições e métodos para diagnóstico tópico e transporte terapêutico
Duncan et al. Commercialization of antifungal peptides
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
MX9207334A (es) Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
AR077455A1 (es) Preparaciones insulinicas de accion lenta
CO6351745A2 (es) Polipéptidos g-csf bovinos modificados y sus usos
MC2144A1 (fr) Peptides therapeutiques
HRP20110386T1 (hr) Sintetička sekvenca mecp2 za zamjensku proteinsku terapiju
AR055179A1 (es) Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas
PE20121799A1 (es) Polipeptidos de somatotropina porcina modificados y sus usos
ES444558A1 (es) Procedimiento para la produccion de una preparacion estable de insulina.
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
CO2020008308A2 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
Moscatiello et al. The intracellular delivery of TAT‐aequorin reveals calcium‐mediated sensing of environmental and symbiotic signals by the arbuscular mycorrhizal fungus G igaspora margarita
NZ755599A (en) Apoc-ii mimetic peptides
Piot et al. Harnessing the membrane translocation properties of AB toxins for therapeutic applications